IGF-1 DES vs NAD+
Side-by-side comparison of key properties, dosing, and research.
- Summary
- IGF-1 DES (also written DES(1-3)IGF-1) is a truncated form of IGF-1 missing the first three amino acids of the N-terminus. This structural change dramatically reduces its affinity for IGF binding proteins (IGFBPs), meaning a far greater fraction remains in its free, active form. IGF-1 DES is estimated to be 10x more potent than standard IGF-1 LR3 at the receptor level locally, making it particularly effective for site-specific muscle growth when injected intramuscularly.
- NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells that declines dramatically with age. It is critical for energy metabolism, DNA repair, and sirtuin activation. IV and subcutaneous NAD+ supplementation is used in anti-aging protocols and addiction recovery programs.
- Half-Life
- ~20–30 minutes (very short — designed for local action)
- Varies by route; IV provides direct cellular delivery
- Admin Route
- IM, SubQ
- IV, SubQ, Oral
- Research
- —
- —
- Typical Dose
- 20–50 mcg per injection site
- 500–1000 mg
- Frequency
- Once daily, post-workout
- Daily for 4–10 days (loading), then monthly maintenance
- Key Benefits
- Estimated 10x greater potency at the receptor vs IGF-1 LR3 locally
- Minimal IGFBP binding — nearly all active upon injection
- Highly localized muscle growth effect when injected intramuscularly
- Activates satellite cells for muscle fiber hyperplasia potential
- Synergistic with GH peptides in post-workout anabolic protocols
- Shorter half-life reduces systemic exposure vs IGF-1 LR3
- Useful for site-specific muscle development
- Restored cellular energy production (ATP)
- Sirtuin activation for longevity and metabolic regulation
- Enhanced DNA repair capacity
- Improved mitochondrial function and biogenesis
- Cognitive clarity and mental energy
- Reduced inflammation
- Addiction withdrawal support (opioids, alcohol, benzodiazepines)
- Improved sleep quality
- Enhanced athletic endurance
- Side Effects
- Hypoglycemia (most significant risk — especially post-workout)
- Localized muscle swelling at injection site
- Potential for jaw/organ growth (acromegalic effects) with prolonged high-dose use
- Carpal tunnel syndrome with high doses
- +1 more
- Flushing and warmth during IV infusion
- Nausea during rapid IV administration
- Chest tightness (from rapid infusion — slow the rate)
- Injection site irritation (subcutaneous)
- +1 more
- Stacks With
- —
- —